Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival
Predicts overall survival in AML patients with relapsed/refractory disease undergoing myeloablative transplant.
INSTRUCTIONS
Use in patients with relapsed or refractory active AML for whom hematopoietic stem cell transplant (HSCT) is being considered. Do not use in patients with chronic myelogenous leukemia (CML) in blast crisis.
When to Use
Pearls/Pitfalls
Why Use
Primary induction failure or duration of first complete remission >6 months
0Duration of first complete remission <6 months
+1Good or intermediate
0Poor
+1HLA identical sibling or well matched or partially matched unrelated
0Mismatched unrelated
+1Related other than HLA identical sibling
+2Absent
0Present
+190-100
0<90
+1Result:
Please fill out required fields.